Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like Novartis AG Hires Bank of America to Officially Review Alcon Options April 20, 2017 Aceto Subsidiary, Rising Pharma, Announces Product Launches July 20, 2017 Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ January 21, 2018
